CLA-1816
CLA-1816 strongly and selectively binds with and activates the alpha3 glycine pain receptor in the spine.
When activated, the alpha3 glycine receptor strongly blocks pain signals from being sent to the brain. To date, no company has introduced into the market an agent specifically targeting this receptor.
The objective of our program is to develop a potent, non-psychotropic, oral analgesic for intractable pain that will be safe and well tolerated. CLA-1816 has the potential to achieve these goals, and become a next generation pain medication.
CLA-1816 has been designed to provide effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics.